Corporate Banner
Satellite Banner
Scientific Community
Become a Member | Sign in
Home>News>This Article

Roche 454 Sequencing Systems Successfully Resolve Genetic Mutations in Blood Cancer Cases

Published: Thursday, December 13, 2012
Last Updated: Thursday, December 13, 2012
Bookmark and Share
International study presented at ASH Meeting demonstrates the potential of 454 Sequencing Systems to comprehensively characterize an individual’s blood cancer type to guide personalized therapy decisions.

At the American Society of Hematology Meeting (ASH) Roche has announced the presentation of results from the large scale study IRON-II through an international research consortium.

Based on next generation 454 Sequencing Systems from Roche, the study aims to characterize selected genes in individuals with a wide range of hematological malignancies.

The consortium of 26 laboratories from 13 countries in Europe and Asia performed comprehensive analysis of 74 genes in individuals with acute myeloid leukemia (AML), acute lymphoblastic leukemia (ALL), chronic lymphatic leukemia (CLL), chronic myelogenous leukemia (CML), myelodysplastic syndromes (MDS), and myeloproliferative neoplasms (MPN).

The results from over 4,000 cases demonstrate that the highly advanced technology supports the comprehensive molecular characterization of hematological malignancies with high sensitivity and specificity, with the future prospect of guiding more personalized treatment decisions.

The study is one of dozens of abstracts and talks using 454 Sequencing Systems presented at the ASH meeting this week.

Researchers from the MLL Munich Leukemia Laboratory, pioneering the adoption of next-generation sequencing to profile blood cancers, are leading the international consortium.

Earlier this year, Roche launched a set of sequence-based primer sets co-developed with the MLL for deep genetic variation detection in the TET2, CBL, KRAS, and RUNX1 genes using the GS FLX and GS Junior Systems.

The current study is an extension of the previous IRON study which demonstrated the robustness, precision and reproducibility of next generation sequencing with 454 Sequencing Systems for characterization of key genes associated with leukemia.

It broadens the set of genes from 3 to 74 with a new expanded set of investigative primer plates.

“We are particularly pleased with the performance of the Roche assays in combination with the high quality long read length of the 454 Sequencing Systems. This is the only technology that allows us to resolve complex variations in genes such as RUNX1 or CEBPA and enables us to address questions such as landmark analyses in various mutated genes in hematological malignancies and the development of future prognostic models,” said Dr. Alexander Kohlmann, Head of the Next Generation Sequencing Group at the MLL and coauthor of 28 studies presented at this year’s conference.

Kohlmann continued, “One key aspect of the IRON-II study is that we now achieved to standardize gene content via amplicon-based deep-sequencing assays across hematological expert laboratories, including the bioinformatic analysis approaches.”

In addition to the consortium results, the MLL Munich Leukemia Laboratory presented novel sequencing data on various disease types including the role of TP53 and CEBPA mutations in AML, or SF3B1 and NOTCH1 mutations in CLL.

“By applying this novel technology we are now in a position to challenge existing schemes for classification and scoring," said Prof. Torsten Haferlach, cofounder and CEO of the MLL. “We can begin to integrate molecular information into more biologically driven models. Ultimately, this could allow us to individualize our approach to treat our patients.”

“We are pleased with the results of the international study, which continues to evaluate the unique value of 454 Sequencing Systems in blood cancer research,” said Thomas Schinecker, President of 454 Life Sciences, a Roche Company.

Schinecker continued, “We are strongly supporting the community with the development of standardized gene panels for molecular characterization of hematological malignancies, which is an important step towards future routine clinical use.”

Further Information
Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 2,800+ scientific posters on ePosters
  • More than 4,000+ scientific videos on LabTube
  • 35 community eNewsletters

Sign In

Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

Roche Introduces Enhanced Whole Exome Sequencing Solution
The company has announced the launch of the SeqCap EZ MedExome Target Enrichment Kit1.
Wednesday, September 23, 2015
Roche to Acquire Kapa Biosystems
Acquisition to strengthen next-generation sequencing product offerings.
Friday, August 21, 2015
Roche's Investigational Immunotherapy Atezolizumab Shrank Tumours in People with Lung Cancer
Roche will discuss results with the U.S. FDA as part of atezolizumab’s Breakthrough Therapy Designation in lung cancer.
Wednesday, August 19, 2015
Pivotal Phase II Study of Venetoclax Met Primary Endpoint
Venetoclax is a small molecule inhibitor of the BCL-2 protein, which potentially represents a new way of treating blood cancers.
Friday, August 14, 2015
Roche, Garvan Institute Epigenomic Partnership
Roche and the Garvan Institute of Medical Research today announce a collaboration to develop new technologies for targeted epigenomic analysis using DNA sequencing.
Wednesday, August 20, 2014
FDA Approves Roche’s Advanced Cervical Cancer Chemotherapy
Avastin is the first biologic medicine approved in combination with chemotherapy to help women with this type of cancer live longer than with chemotherapy alone.
Monday, August 18, 2014
Roche to Acquire Seragon Pharmaceuticals
Acquisition of Phase I program offers a potential new approach for hormone receptor-positive breast cancer.
Wednesday, July 02, 2014
Roche Invests in Stratos Genomics
Investment by Roche will advance Stratos Genomics chemistry for nanopore sequencing.
Friday, June 27, 2014
Roche Recieves FDA Approval for Cervical Cancer Screening HPV Test
Expanded indication makes cobas HPV Test the only test approved in U.S. that can be used instead of Pap in first-line primary screening in women 25 and older.
Friday, April 25, 2014
Roche, Oryzon Announce Epigenetics Collaboration
Collaboration spans research, development and commercialization of LSD1 inhibitors for oncology, haematology and non-malignant conditions.
Monday, April 07, 2014
FDA Recommends Roche's HPV Test as Primary Screening Tool
Test will assess risk of cervical cancer of women 25 years and older.
Thursday, March 13, 2014
Roche and Molecular Partners Enter into Alliance
Partnership will combine novel biologics with Roche drug-conjugate technology to develop new cancer treatments.
Wednesday, December 04, 2013
FDA Approves New Streamlined Workflow Option for Roche's Cobas HPV Test
New process allows labs to use same Pap test vial instead of transferring sample to new vial, thus simplifying workflow.
Friday, June 28, 2013
Roche 454 Life Sciences and SoftGenetics Sign Co-Promotion Agreement
Agreement designed to provide users next-gen sequencing software tools.
Thursday, May 10, 2012
Roche Supports the Smithsonian's National Zoo with Next-Generation Sequencing Instrument
Companies reach collaboration agreement in which zoo will use Roche's GS Junior benchtop sequencing system for research in SCBI's Center for Conservation and Evolutionary Genetics.
Thursday, February 09, 2012
Scientific News
Exploring the Causes of Cancer
Queen's research to understand the regulation of a cell surface protein involved in cancer.
Ancient Viral Molecules Essential for Human Development
Genetic material from ancient viral infections is critical to human development, according to researchers at the Stanford University School of Medicine.
Tardigrade's Are DNA Master Thieves
Tardigrades, nearly microscopic animals that can survive the harshest of environments, including outer space, hold the record for the animal that has the most foreign DNA.
The Secret Behind the Power of Bacterial Sex
Migration between different communities of bacteria is the key to the type of gene transfer that can lead to the spread of traits such as antibiotic resistance, according to researchers at Oxford University.
Farming’s in Their DNA
Ancient genomes reveal natural selection in action.
GMO Food Animals Should be Judged by Product, Not Process
In a world with a burgeoning demand for meat, milk and eggs, regulatory policies around the use of biotechnologies in agriculture need to be based on the safety and attributes of those foods rather than on the methods used to produce them, says a UC Davis animal scientist.
Enzyme Critical to Maintaining Telomere Length Discovered
New method expected to speed understanding of short telomere diseases and cancer.
Gene Drive Reversibility Introduces New Layer of Biosafety
Ability to introduce or reverse the spread of genetic traits through populations could one day improve pest management and disease control.
RNA-Based Drugs Give More Control Over Gene Editing
CRISPR/Cas9 gene editing technique can be transiently activated and inactivated using RNA-based drugs, giving researchers more precise control in correcting and inactivating genes.
University of Glasgow Researchers Make An Impact in 60 Seconds
Early-career researchers were invited to submit an engaging, dynamic and compelling 60 second video illuminating an aspect of their research.
Skyscraper Banner

Skyscraper Banner
Go to LabTube
Go to eposters
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
2,800+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
4,000+ scientific videos